Will a new drug formula absorb better? a trial in healthy adults aims to find out

NCT ID NCT07752069

Not yet recruiting Knowledge-focused Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This Phase 1 trial is testing two different formulations of an experimental drug called HRS-5346 in healthy adults aged 18 to 45. The goal is to compare how well the body absorbs each version, which helps guide future development. Participants receive both formulations in a crossover design, and researchers measure drug levels in the blood along with safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-5346 (an experimental drug being tested in two different formulations)
What this could lead to: If the new formulation is absorbed as well as the old one, it could support the development of HRS-5346 as a potential treatment for lipoprotein disorders.
What could go wrong: This is an early-stage trial in healthy volunteers, not patients. Results may not predict how the drug works in people with the condition, and the drug could still fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIPOPROTEIN DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIPOPROTEIN DISORDER

Contacts and locations

Locations

Beijing Hospital

Beijing, Beijing Municipality, 100005, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.